Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	I. N. Dyakov [verfasserIn] S. K. Zyryanov [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2021

Schlagwörter:	сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт

Übergeordnetes Werk:	In: Качественная клиническая практика - Izdatelstvo OKI, 2020, (2021), 1, Seite 4-15
Übergeordnetes Werk:	year:2021 ; number:1 ; pages:4-15

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.37489/2588-0519-2021-1-4-15

Katalog-ID:	DOAJ097192945

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ097192945
003	DE-627
005	20240413174533.0
007	cr uuu---uuuuu
008	240413s2021 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.37489/2588-0519-2021-1-4-15 \|2 doi
035			\|a (DE-627)DOAJ097192945
035			\|a (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a R855-855.5
050		0	\|a RS1-441
100	0		\|a I. N. Dyakov \|e verfasserin \|4 aut
245	1	0	\|a Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.
650		4	\|a сахарный диабет
650		4	\|a фармакоэкономика
650		4	\|a инсулин гларгин 300 ед/мл
650		4	\|a инсулин деглудек
650		4	\|a инсулин деглудек / инсулин аспарт
653		0	\|a Medical technology
653		0	\|a Pharmacy and materia medica
700	0		\|a S. K. Zyryanov \|e verfasserin \|4 aut
773	0	8	\|i In \|t Качественная клиническая практика \|d Izdatelstvo OKI, 2020 \|g (2021), 1, Seite 4-15 \|w (DE-627)1760591807 \|x 26188473 \|7 nnns
773	1	8	\|g year:2021 \|g number:1 \|g pages:4-15
856	4	0	\|u https://doi.org/10.37489/2588-0519-2021-1-4-15 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 \|z kostenfrei
856	4	0	\|u https://www.clinvest.ru/jour/article/view/555 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2588-0519 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2618-8473 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|j 2021 \|e 1 \|h 4-15

Indexfelder

author_variant	i n d ind s k z skz
matchkey_str	article:26188473:2021----::hraocnmcoprsnfhscngnrtoislnnlg
hierarchy_sort_str	2021
callnumber-subject-code	R
publishDate	2021
allfields	10.37489/2588-0519-2021-1-4-15 doi (DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 I. N. Dyakov verfasserin aut Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment. сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica S. K. Zyryanov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2021), 1, Seite 4-15 (DE-627)1760591807 26188473 nnns year:2021 number:1 pages:4-15 https://doi.org/10.37489/2588-0519-2021-1-4-15 kostenfrei https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 kostenfrei https://www.clinvest.ru/jour/article/view/555 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 1 4-15
spelling	10.37489/2588-0519-2021-1-4-15 doi (DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 I. N. Dyakov verfasserin aut Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment. сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica S. K. Zyryanov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2021), 1, Seite 4-15 (DE-627)1760591807 26188473 nnns year:2021 number:1 pages:4-15 https://doi.org/10.37489/2588-0519-2021-1-4-15 kostenfrei https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 kostenfrei https://www.clinvest.ru/jour/article/view/555 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 1 4-15
allfields_unstemmed	10.37489/2588-0519-2021-1-4-15 doi (DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 I. N. Dyakov verfasserin aut Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment. сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica S. K. Zyryanov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2021), 1, Seite 4-15 (DE-627)1760591807 26188473 nnns year:2021 number:1 pages:4-15 https://doi.org/10.37489/2588-0519-2021-1-4-15 kostenfrei https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 kostenfrei https://www.clinvest.ru/jour/article/view/555 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 1 4-15
allfieldsGer	10.37489/2588-0519-2021-1-4-15 doi (DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 I. N. Dyakov verfasserin aut Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment. сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica S. K. Zyryanov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2021), 1, Seite 4-15 (DE-627)1760591807 26188473 nnns year:2021 number:1 pages:4-15 https://doi.org/10.37489/2588-0519-2021-1-4-15 kostenfrei https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 kostenfrei https://www.clinvest.ru/jour/article/view/555 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 1 4-15
allfieldsSound	10.37489/2588-0519-2021-1-4-15 doi (DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 I. N. Dyakov verfasserin aut Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment. сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica S. K. Zyryanov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2021), 1, Seite 4-15 (DE-627)1760591807 26188473 nnns year:2021 number:1 pages:4-15 https://doi.org/10.37489/2588-0519-2021-1-4-15 kostenfrei https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 kostenfrei https://www.clinvest.ru/jour/article/view/555 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 1 4-15
language	Russian
source	In Качественная клиническая практика (2021), 1, Seite 4-15 year:2021 number:1 pages:4-15
sourceStr	In Качественная клиническая практика (2021), 1, Seite 4-15 year:2021 number:1 pages:4-15
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт Medical technology Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Качественная клиническая практика
authorswithroles_txt_mv	I. N. Dyakov @@aut@@ S. K. Zyryanov @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1760591807
id	DOAJ097192945
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097192945</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174533.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2021 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37489/2588-0519-2021-1-4-15</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097192945</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">I. N. Dyakov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c &lt;7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин 300 ед/мл</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек / инсулин аспарт</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. K. Zyryanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2021), 1, Seite 4-15</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:4-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37489/2588-0519-2021-1-4-15</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/555</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">4-15</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	I. N. Dyakov
spellingShingle	I. N. Dyakov misc R855-855.5 misc RS1-441 misc сахарный диабет misc фармакоэкономика misc инсулин гларгин 300 ед/мл misc инсулин деглудек misc инсулин деглудек / инсулин аспарт misc Medical technology misc Pharmacy and materia medica Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
authorStr	I. N. Dyakov
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760591807
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	R855-855
illustrated	Not Illustrated
issn	26188473
topic_title	R855-855.5 RS1-441 Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base сахарный диабет фармакоэкономика инсулин гларгин 300 ед/мл инсулин деглудек инсулин деглудек / инсулин аспарт
topic	misc R855-855.5 misc RS1-441 misc сахарный диабет misc фармакоэкономика misc инсулин гларгин 300 ед/мл misc инсулин деглудек misc инсулин деглудек / инсулин аспарт misc Medical technology misc Pharmacy and materia medica
topic_unstemmed	misc R855-855.5 misc RS1-441 misc сахарный диабет misc фармакоэкономика misc инсулин гларгин 300 ед/мл misc инсулин деглудек misc инсулин деглудек / инсулин аспарт misc Medical technology misc Pharmacy and materia medica
topic_browse	misc R855-855.5 misc RS1-441 misc сахарный диабет misc фармакоэкономика misc инсулин гларгин 300 ед/мл misc инсулин деглудек misc инсулин деглудек / инсулин аспарт misc Medical technology misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Качественная клиническая практика
hierarchy_parent_id	1760591807
hierarchy_top_title	Качественная клиническая практика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760591807
title	Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
ctrlnum	(DE-627)DOAJ097192945 (DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4
title_full	Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
author_sort	I. N. Dyakov
journal	Качественная клиническая практика
journalStr	Качественная клиническая практика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	4
author_browse	I. N. Dyakov S. K. Zyryanov
class	R855-855.5 RS1-441
format_se	Elektronische Aufsätze
author-letter	I. N. Dyakov
doi_str_mv	10.37489/2588-0519-2021-1-4-15
author2-role	verfasserin
title_sort	pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
callnumber	R855-855.5
title_auth	Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
abstract	Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.
abstractGer	Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.
abstract_unstemmed	Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
url	https://doi.org/10.37489/2588-0519-2021-1-4-15 https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4 https://www.clinvest.ru/jour/article/view/555 https://doaj.org/toc/2588-0519 https://doaj.org/toc/2618-8473
remote_bool	true
author2	S. K. Zyryanov
author2Str	S. K. Zyryanov
ppnlink	1760591807
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.37489/2588-0519-2021-1-4-15
callnumber-a	R855-855.5
up_date	2024-07-04T00:10:30.787Z
_version_	1803605068523503616
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097192945</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174533.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2021 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37489/2588-0519-2021-1-4-15</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097192945</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf6f7de9fabaa4352b76368dc57dd56c4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">I. N. Dyakov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c &lt;7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин 300 ед/мл</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек / инсулин аспарт</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. K. Zyryanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2021), 1, Seite 4-15</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:4-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37489/2588-0519-2021-1-4-15</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/555</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">4-15</subfield></datafield></record></collection>
score	7.401886

Nicht das Richtige dabei?

Schreiben Sie uns!

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?